RP1

Unassigned

New Medicines

Advanced cutaneous squamous cell carcinoma (cSCC) - in combination with cemiplimab

Information

Advanced therapy medicinal product (ATMP)
Replimune
Replimune

Development and Regulatory status

None
None
Phase II Clinical Trials

Category

Oncolytic immunotherapy based on a new strain of herpes simplex virus, engineered for tumour selectivity & enhanced systemic potency, through the expression of a potent fusogenic glycoprotein from gibbon ape leukemia virus (GALV-GP R) and GM-CSF.
Incidence of SCC is about 10,000 per year in England and Wales. The incidence is higher in Caucasians [1].
Advanced cutaneous squamous cell carcinoma (cSCC) - in combination with cemiplimab
Intratumoural

Trial or other data

Oct 19 · PII CERPASS trial to evaluate the efficacy of RP 1 in combination with cemiplimab in patients with locally advanced or metastatic cSCC starts (RPL-002-18; NCT04050436). 240 adults will be recruited in Australia and the US. Primary outcome is objective response rate; collection of these data is due to complete Oct 22 [2].